N

Nykode Therapeutics ASA
OSE:NYKD

Watchlist Manager
Nykode Therapeutics ASA
OSE:NYKD
Watchlist
Price: 2.47 NOK -0.72% Market Closed
Market Cap: 806.6m NOK

Intrinsic Value

NYKD's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

The intrinsic value of one NYKD stock under the Base Case scenario is 2.77 NOK. Compared to the current market price of 2.47 NOK, Nykode Therapeutics ASA is Undervalued by 11%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

NYKD Intrinsic Value
2.77 NOK
Undervaluation 11%
Intrinsic Value
Price
N
Worst Case
Base Case
Best Case

Valuation History
Nykode Therapeutics ASA

Intrinsic Value History
Dive into the past to invest in the future

Uncover deeper insights with the Valuation History. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start now and learn if your stock is truly undervalued or overvalued!

Start Valuation
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
NYKD
Valuation History
HIDDEN
Show
Valuation History Unavailable

Historical valuation for NYKD cannot be conducted due to limitations such as insufficient data or other constraints.

Valuation In Progress...
Valuation In Progress...
0%

Fundamental Analysis

Nykode Therapeutics ASA
OSE:NYKD
NO
Biotechnology
Market Cap
806.6m NOK
IPO
Jan 27, 2020
NO
Biotechnology
Market Cap
806.6m NOK
IPO
Jan 27, 2020
Price
krfalse
EPS
$false
AI Assistant
AI Assistant
Ask me anything about Nykode Therapeutics ASA
Financials
Annual
Quarterly
TTM

Balance Sheet Decomposition
Nykode Therapeutics ASA

Current Assets 117.1m
Cash & Short-Term Investments 115.4m
Receivables 1.7m
Non-Current Assets 36.4m
PP&E 7.7m
Intangibles 72k
Other Non-Current Assets 28.6m
Efficiency

Free Cash Flow Analysis
Nykode Therapeutics ASA

Last Value
3-Years Average
FCF Margin
Conversion Rate

Earnings Waterfall
Nykode Therapeutics ASA

Revenue
8.7m USD
Operating Expenses
-57m USD
Operating Income
-48.3m USD
Other Expenses
9.5m USD
Net Income
-38.8m USD
Fundamental Scores

NYKD Profitability Score
Profitability Due Diligence

Nykode Therapeutics ASA's profitability score is 9/100. The higher the profitability score, the more profitable the company is.

9/100
Profitability
Score

Nykode Therapeutics ASA's profitability score is 9/100. The higher the profitability score, the more profitable the company is.

NYKD Solvency Score
Solvency Due Diligence

Nykode Therapeutics ASA's solvency score is 75/100. The higher the solvency score, the more solvent the company is.

High Altman Z-Score
Short-Term Solvency
Long-Term Solvency
Negative Net Debt
75/100
Solvency
Score

Nykode Therapeutics ASA's solvency score is 75/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

NYKD Price Targets Summary
Nykode Therapeutics ASA

Wall Street analysts forecast NYKD stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for NYKD is 5.44 NOK with a low forecast of 2.53 NOK and a high forecast of 8.93 NOK.

Lowest
Price Target
2.53 NOK
2% Upside
Average
Price Target
5.44 NOK
120% Upside
Highest
Price Target
8.93 NOK
261% Upside
View Analyst Estimates
View Analyst Estimates

Dividends

Nykode Therapeutics ASA
does not pay dividends
Shareholder Yield

Current shareholder yield for NYKD is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest
What is the Intrinsic Value of one NYKD stock?

The intrinsic value of one NYKD stock under the Base Case scenario is 2.77 NOK.

Is NYKD stock undervalued or overvalued?

Compared to the current market price of 2.47 NOK, Nykode Therapeutics ASA is Undervalued by 11%.

Back to Top